

Application for United States Letters Patent

To all whom it may concern:

Be it known that, we,

Timothy Norris, Jeffrey W. Raggon, Richard D. Connell, James D. Moyer, Michael J. Morin, Shana M. Kajiji, Barbara A. Foster, Karen J. Ferrante and Sandra L. Silberman

have invented certain new and useful improvements in

STABLE POLYMORPH OF N-(3-ETHYNYLPHENYL)-6, 7-BIS (2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF

of which the following is a full, clear and exact description.

#23



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

policants

Timothy Norris et al.

Serial No.

09/711,272

Group Art Unit: 1624

Filed

November 9, 2000

Examiner: T. McKenzie

For

STABLE POLYMORPH OF N-(3-ETHYNYLPHENYL)-6, 7-BIS (2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND

PHARMACEUTICAL USES THEREOF

1185 Avenue of the Americas New York, New York 10036 September 18, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL AMENDMENT AND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

A Notice of Allowance was issued in connection with the aboveidentified application by the U.S. Patent and Trademark Office on
June 18, 2003 requiring payment of the issue fee by September 18,
2003. Instead of paying the issue fee, applicants are filing a
Request for Continued Examination ("RCE") with this Supplemental
Amendment and Supplemental Information Disclosure Statement being
the "submission" pursuant to 37 C.F.R. §1.114. Accordingly, the
subject application is pending today and this Supplemental
Amendment and Supplemental Information Disclosure Statement is
being timely filed.

RCH CENTER BOOMS